2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1350

Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis
Abstract Number: 1351

In Situ Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies
Abstract Number: 1352

Low Density Granulocytes in Idiopathic Inflammatory Myopathy
Abstract Number: 1353

Autophagy Marker LC3 Accumulates in Immune-Mediated Necrotizing Myopathy Muscle Fibres
Abstract Number: 1354

Correlates of Neuropathic Pain in Knee Osteoarthritis: The Modified Paindetect Questionnaire and the Osteoarthritis Initiative
Abstract Number: 1355

Asymptomatic Hyperuricemia Is Associated with Increased Prevalence of Symptomatic Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey
Abstract Number: 1356

Increasing Oral Doses of GLPG1972 Administered Daily for 29 Days Show a Strong Target Engagement in Patients with Knee and/or Hip OA
Abstract Number: 1357

Flexion Contractures Are Associated with Worse Pain, Stiffness, and Function in Patients with Knee Osteoarthritis
Abstract Number: 1358

The Association of Microbial Translocation and WOMAC Function in Patients with Knee Osteoarthritis
Abstract Number: 1359

A Machine Learning Approach to Knee OA Phenotyping: The Johnston County Osteoarthritis Project
Abstract Number: 1360

The Role of Personality in Patients with Knee Osteoarthritis
Abstract Number: 1361

Predictive Modeling of Therapeutic Response in Knee Osteoarthritis
Abstract Number: 1362

Magnetic Resonance Imaging Features Can Classify Adults Who Will Develop Accelerated Knee Osteoarthritis
Abstract Number: 1363

Progression of Pain, Stiffness, Function Changes, and Ultrasound Detected Synovitis and Osteophyte Formation in Patients with Hand Osteoarthritis over Three Years
Abstract Number: 1364

Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].